Nice Holdings Inc lowers consolidated mid-year and full-year outlook and reaffirms year-end dividend for FY 2015
Nice Holdings Inc:Says the company lowered the consolidated mid-year outlook for revenue to 105,000 million yen from 115,000 million yen for the fiscal year ending March 31, 2015.Sees a decrease of mid-year operating profit forecast to a loss of 1,500 million yen from a loss of 600 million yen.Sees a decrease of mid-year ordinary profit forecast to a loss of 1,800 million yen from a loss of 900 million yen.Sees a decrease of mid-year net profit forecast to a loss of 1,800 million yen from a loss of 1,400 million yen.Sees a decrease of mid-year earnings per share to a loss of 19.19 yen from a loss of 14.92 yen.Says the company lowered the consolidated full-year outlook for revenue to 250,000 million yen from 267,000 million yen for the fiscal year ending March 31, 2015.Sees a decrease of full-year operating profit forecast to 900 million yen from 2,850 million yen.Sees a decrease of full-year ordinary profit forecast to 700 million yen from 1,900 million yen.Sees a decrease of full-year net profit forecast to 500 million yen from 1,100 million yen.Sees a decrease of full-year earnings per share to 5.33 yen from 11.72 yen.Comments that decreased sales of construction material business and decreased construction orders are the main reasons for the forecast.Confirms year-end dividend of 4 yen per share for the fiscal year ending March 31, 2015.
WCM Beteiligungs und Grundbesitz AG says the only remaining bankruptcy proceedings formality is completed
WCM Beteiligungs und Grundbesitz AG:Says after termination of insolvency proceedings against the assets of WCM AG, surveillance plan was arranged.Says insolvency administrator was appointed as plan supervisor.Says thus, the only remaining bankruptcy proceedings formality is done.
Revive Therapeutics Ltd submits IND application to US FDA for the clinical development of Bucillamine for the treatment of Gout
Revive Therapeutics Ltd:Says that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the clinical development of REV-002 (Bucillamine).Says for the treatment of gout. Pending FDA review of the IND application, the company plans to initiate a Phase II-A human proof of concept study in patients with gout.This IND submission follows Revive's recently announced pre-IND submission to the FDA and its announcement that it has signed a material transfer agreement (the MTA) with global pharmaceutical company headquartered in Osaka, Japan.The MTA has allowed Revive to obtain access to confidential information and clinical trial supply of Bucillamine for U.S.-based trial.
Hydra Industries Acquisition Corp:Closes its initial public offering of 8 million units at an offering price of $10.00 per unit, resulting in gross proceeds of $80 mln, before underwriting discounts and commissions and offering expenses.Company has granted the underwriters a 45-day option to purchase up to an additional 1.2 mln units to cover over-allotments, if any, in the public offering.Company is a newly organized blank check company formed for the purpose of effecting a merger or other business combination with a target company.Proceeds of the offering will be used in connection with such business combination.UBS Investment Bank acted as sole book-running manager and EarlyBirdCapital, Inc. acted as co-manager for the offering.
Naked Brand Group Inc:On Oct. 22, approved dismissal of BDO Canada LLP as independent registered public accounting firm.Company is seeking appointment of independent registered public accounting firm in closer proximity to new head office in New York, NY, USA.
ZD Ventures CorpZD Ventures Corp:Kam Shah resigned his positions as a chief executive officer and president effective Sept. 30.Terence Robinson was appointed as president and chief executive officer.
Goldis Bhd:Has acquired entire issued and paid-up capital in Silver Sanctuary Sdn Bhd.Says acquisition comprising 2 ordinary shares of 1Ringgit each for cash consideration of 2 Ringgit resulting in Silver Sanctuary Sdn Bhd becoming wholly-owned subsidiary.
Hydra Industries Acquisition Corp:Prices its initial public offering of 8 mln units at an offering price of $10.00 per unit, each consisting of one share of its common stock.Says one warrant to purchase one-half of one share of its common stock and one right which, upon consummation of an initial business combination, entitles holder thereof to receive one-tenth of one share of its common stock.Hydra Industries Acquisition Corp. is newly organized blank check company formed for purpose of effecting a merger or other business combination with target company.Says proceeds of offering will be used to fund such business combination.The units are expected to begin trading, Oct. 24 on NASDAQ Stock Market under symbol HDRAU.Once securities comprising units begin separate trading, common stock, warrants and rights are expected to be listed on NASDAQ Stock Market under the symbols HDRA, HDRAW and HDRAR, respectively.Says UBS Investment Bank is acting as sole book-running manager and EarlyBirdCapital, Inc. is acting as co-manager for offering.Says Hydra Industries Acquisition Corp. has granted the underwriters 45-day option to purchase up to an additional 1.2 mln units to cover over-allotments, if any, in public offering.
Zhuhai Boyuan Investment Co Ltd:Says change in accounting policy due to new accounting standards announced by Ministry of Finance of the People's Republic of China, effective July 1.
Rodeo Capital III Corp:Enters into arm's length non-binding letter agreement with Solegear Bioplastics Inc., which contemplates that Rodeo will acquire all of the issued and outstanding common shares of Solegear from the holders of the Solegear Shares in exchange for the issuance of Rodeo common shares.Says exact number of Rodeo Shares to be issued to Solegear Shareholders is still to be determined.Completion of the Transaction is subject to the settlement and execution of a definitive purchase agreement to be negotiated and settled by Rodeo and Solegear by Nov. 21, or such later date as may be agreed to by the parties.Parties have agreed that Closing of the Transaction will occur on or before Jan. 30, 2015.Says Solegear has agreed to purchase or to cause a third party to purchase within escrow a minimum of 880,000 Rodeo Shares held by the principals of Rodeo, up to a maximum of 1.24 million Rodeo shares, at a price of $0.07 per Rodeo Share.Says it is currently contemplated that post Closing, the name of Rodeo will be changed to Solegear Bioplastics Inc.